Serum metabolic profiling identified a distinct metabolic signature in patients with idiopathic pulmonary fibrosis - a potential biomarker role for LysoPC. by Rindlisbacher, Barbara et al.
RESEARCH Open Access
Serum metabolic profiling identified a
distinct metabolic signature in patients
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Abstract
Background: Idiopathic pulmonary fibrosis (IPF) is a lethal lung disease of unknown etiology. Patients present loss
of lung function, dyspnea and dry cough. Diagnosis requires compatible radiologic imaging and, in undetermined
cases, invasive procedures such as bronchoscopy and surgical lung biopsy. The pathophysiological mechanisms of
IPF are not completely understood. Lung injury with abnormal alveolar epithelial repair is thought to be a major
cause for activation of profibrotic pathways in IPF. Metabolic signatures might indicate pathological pathways
involved in disease development and progression. Reliable serum biomarker would help to improve both diagnostic
approach and monitoring of drug effects.
Method: The global metabolic profiles measured by ultra high-performance liquid chromatography coupled to
high-resolution mass spectrometry (UHPLC-HRMS) of ten stable IPF patients were compared to the ones of ten
healthy participants. The results were validated in an additional study of eleven IPF patients and ten healthy
controls.
Results: We discovered 10 discriminative metabolic features using multivariate and univariate statistical analysis.
Among them, we identified one metabolite at a retention time of 9.59 min that was two times more abundant in
the serum of IPF patients compared to healthy participants. Based on its ion pattern, a lysophosphatidylcholine
(LysoPC) was proposed. LysoPC is a precursor of lysophosphatidic acid (LPA) – a known mediator for lung fibrosis
with its pathway currently being evaluated as new therapeutic drug target for IPF and other fibrotic diseases.
Conclusions: We identified a LysoPC by UHPLC-HRMS as potential biomarker in serum of patients with IPF.
Further validation studies in a larger cohort are necessary to determine its role in IPF.
Trial Registration: Serum samples from IPF patients have been obtained within the clinical trial NCT02173145 at
baseline and from the idiopathic interstitial pneumonia (IIP) cohort study. The study was approved by the Swiss
Ethics Committee, Bern (KEK 002/14 and 246/15 or PB_2016–01524).
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Background
Idiopathic pulmonary fibrosis (IPF) is a severe and pro-
gressive fibrosing interstitial lung disease with sinister
prognosis. The median survival is about 3–5 years after
onset of symptoms, although there are various disease
progression patterns [1–3]. Patients present with unspe-
cific symptoms and signs, such as dyspnea on exertion,
bibasilar inspiratory crackles and non-productive cough
[4, 5]. Males over 60 years with a history of smoking
have an increased risk to develop IPF. Still the exact
cause remains unknown [6, 7]. Abnormal alveolar epi-
thelial wound healing with activation of pro-fibrotic
pathways is considered as a major initiating event for
IPF [8]. In addition, accumulation of myofibroblasts and
production of extracellular matrix leads to scarring of
lung tissue with loss of function [9]. Several pro-fibrotic
pathways involved in the pathogenesis of IPF have been
identified and targeted for drug development [10].
Today, disease-modifying drugs are available, but none
of them leads to a cure. Anti-fibrotic treatment mainly
slows down disease progression [11].
IPF is diagnosed in a multidisciplinary setting with
typical patterns in high resolution computed tomog-
raphy (HRCT) and, if necessary, invasive methods as
bronchoscopy and lung biopsy [1]. The diagnosis is
made if typical criteria of usual interstitial pneumonia
(UIP) pattern are fulfilled in HRCT and/ or in lung bi-
opsy and other causes of interstitial lung diseases (ILD)
have been excluded [1]. Invasive procedures are of risk
for respiratory-impaired patients and not always pos-
sible. Less invasive methods are urgently needed to
facilitate the diagnostic, prognostic and therapeutic
monitoring strategies. Blood is easy to obtain without
putting the patients at risk. Unfortunately, no serum or
plasma biomarkers have been established in clinical rou-
tine so far and new biomarker candidates are urgently
needed [12].
Nowadays, global metabolic profiling using ultra
high-performance liquid chromatography coupled to
high-resolution mass spectrometry (UHPLC-HRMS)
offers the possibility to discover pathologically regu-
lated molecules. These molecules might give informa-
tion about aberrant metabolic pathways in a disease.
Characteristic metabolites might offer the opportunity
to understand pathological processes and to discover
new potential diagnostic and/or prognostic biomarkers
[13]. To our knowledge, no study investigating the
global blood metabolic profile from IPF patients by
UHPLC-HRMS is currently available. This approach
has been recently used to identify metabotypes of
asthma severity [14]. For IPF, proposed biomarkers
belong to chemokines (IL-8, CCL18), proteases
(MMP-1 and MMP- 7), and growth factors (IGBPs)
families [15]. None of these proteins biomarkers has
been established in clinical routine. In this study, we
aimed to search for different metabolic profiles to
identify new possible pathways and potential bio-
markers for IPF.
Methods
Study cohort
For the pilot and validation study, serum samples of
patients with stable IPF (n = 10, n = 11 respectively) and
control subjects (n = 10, n = 11 respectively) were ob-
tained from the Department for Pulmonary Medicine,
University Hospital, Inselspital, Bern, Switzerland and
stored by −80 °C until analysis. IPF was diagnosed
according to the current international guidelines of 2011
[1]. High resolution chest CT scans of IPF patients were
evaluated by a radiologist experienced in ILD diagnosis.
If necessary, a histological evaluation including face-to-
face multidisciplinary discussion with the treating pul-
monologists, pathologists and radiologists was done.
Clinical baseline characteristics, including smoking habits
and lung function, were assessed and documented. Part of
the serum samples from IPF patients have been obtained
within the clinical trial NCT02173145 at baseline and
from the idiopathic interstitial pneumonia (IIP) cohort
study. The study protocol was approved by the local
Ethics Committee (Swiss Ethics Committee, Bern (KEK
002/14 and 246/15 or PB_2016–01524)) and all partici-
pants signed written informed consent to participate.
Sample preparation
Serum metabolites were extracted with organic solvent
for protein precipitation. Frozen serum was gently
thawed at 4 °C. 250 μL of −20 °C cold methanol:acetoni-
trile (1:1, v/v) containing chlorpropamide as internal
standard (1 μg/mL) was added to 50 μL serum in a
1.5 mL CapLock tube. Samples were shortly vortexed,
stored at −80 °C for 30 min and then centrifuged twice
at 14′000 g for 20 min at 4 °C. The supernatants were
transferred into total recovery liquid chromatography –
mass spectrometry (LC-MS) vials. In addition to the
serum samples, a blank sample was similarly extracted
(water collected in a similar CapLock tube used for sam-
ple preparation). Pooled group samples were generated
by combining 50 μL of each samples from the same
group. A pooled quality control (QC) sample was gener-
ated by mixing 50 μL of the pooled group samples. The
final serum extracts were stored at 6 °C until analysis.
UHPLC-HRMS and TWIM-MS analysis
The serum extracts were analyzed in a randomized block
design order on a high resolution mass spectrometer
(Synapt G2-S HDMS, Waters, Milford, MA, USA)
coupled to a 2D UPLC Acquity I-Class system (Waters,
Milford, MA, USA). Two μL of the extracted metabolites
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were separated on a ACQUITY UPLC HSS T3 column
(1.0 mm × 100 mm, 1.8 μm, Waters) at a flow rate of
0.17 mL/min. The mobile phase was composed of 0.1%
(v/v) formic acid in (A) 1% (v/v) methanol in H2O and
(B) methanol. The following LC gradient was applied:
0 min: 100% mobile phase A, 1 min: 100% A, 11 min:
1% A, 13.0 min: 1% A, 13.1 min: 100% A, 15 min: 100%
A. The column temperature was set to 50 °C and the
autosampler to 6 °C. Standard mass spectrometric pa-
rameters were 0.5 kV and 20 V for capillary voltage and
cone voltage, respectively. Desolvation and source
temperature were kept at 450 °C and 120 °C, respect-
ively. Cone and desolvation flows were set to 150 L/h
and 800 L/h, respectively. Leucine-Enkephalin ([M +
H]+m/z = 556.2766, [M-H]−m/z = 554.2620) was acquired
every 20 s for lock mass correction. Mass spectra were
acquired at a scan time of 0.2 s in the MSE resolution
mode between m/z 50 and 1200. In addition, data-
dependent acquisition (DDA) MS/MS experiments were
performed on the pooled group and QC samples. Before
sample analysis, the system was equilibrated by injecting
10 times the QC sample and the QC sample was then
analyzed after every fifth sample injection. A system suit-
ability test (SST) containing standards was measured at
the beginning and the end of the analytical run to ensure
retention time stability, intensity stability and mass
error ≤ 8 ppm. The instrument was controlled via Mas-
sLynx (version 4.1, Waters). The pilot study set was ana-
lyzed with one replicate per IPF patient and healthy
control sample, whereas for the validation set, duplicate
analysis was applied.
To improve structural elucidation of the regulated
metabolites, traveling wave ion mobility mass spec-
trometry (TWIM-MS) of extracted serum was add-
itionally performed. Extracted serum was separated
under the same chromatographic conditions described
above. Mass spectra were acquired in the positive and
negative ionization mode at a scan time of 0.5 s in
the HDMSE resolution mode between m/z 50 and
1200. The TWIM wave height was set at 40 V and
the wave velocity was ramped from 1000 to 300 m/s.
Precursors were fragmented after the TWIM separ-
ation in the transfer T-cell set and transferred to the
TOF at a velocity of 220 m/s. The ion mobility was
calibrated with poly-DL-alanine, which allowed the
determination of the collision cross section (CCS) in
nitrogen [16]. A lipid standard mixture of phosphati-
dylcholines (PC(18:0/0:0), PC(18:2/0:0), PC(12:0/12:0),
PC(14:0/14:0), PC(18:1/18:1), PC(16:0/0:0) obtained
from Echelon Biosciences) was prepared in acetonitri-
le:isopropanol:water (2:1:1, v/v) and used as quality
control for the CCS measurements. Two μL of this
lipid standard mixture at 0.1 and 1.0 μg/mL were
analyzed by UHPLC-TWIM-MS in the positive and
negative ESI mode, respectively. Data processing was
performed using UNIFI (version 1.8.2.169, Waters,
Millford, USA).
Data processing and statistical analysis
After lock-mass correction and chromatographic align-
ment with Progenesis QI (version 2.2, Nonlinear Dynam-
ics, Newcastle, UK), ion patterns were deconvoluted
between 0.45–11.5 min. As possible ions, [M +H]+, [M +
Na]+, [M +K]+, [M +H-H2O]
+, [M +H-2H2O]
+, [M + 2H]2
+, [M + 3H]3+, [2M+H]+, [2 M +Na]+ and [2M+K]+ were
defined in the positive ion mode, [M-H]−, [M-H-H2O]
−,
[M +HCOOH-H]−, [M-2H]2−, [M-3H]3− and [2M-H]− in
the negative ion mode. The abundances of the features
were normalized to all compounds. Features eluting be-
tween 0.5–10.5 min with a chromatographic peak width ≥
0.05 min, having a coefficient of variation of the peak
area ≤ 30% in the QC samples, singly charged ions and ions
having a maximum abundance across all samples ≥200
(positive mode, arbitrary threshold) or ≥150 (negative
mode, arbitrary threshold), were selected for further evalu-
ation. In addition, the metabolic features having an abun-
dance in blank higher than in QC and which were at least
twice more abundant in blank were excluded. Known
drug/drug metabolites taken from patient were also
excluded from the dataset.
The normalized abundances of each filtered metabolic
features were subjected to multivariate and univariate stat-
istical analysis. For the validation set, the features abun-
dances of the duplicate analysis were averaged. For
multivariate statistical analysis, data were subjected to Pa-
reto scaling prior to orthogonal projections of latent struc-
tures discriminant analysis (OPLS-DA) with SIMCA
(version 14, Umetrics, Umeå, Sweden). Results were further
integrated if the n-fold (n = total number of sample, leave-
one-out cross validation approach) cross-validated
correlation Q2(cum) was ≥0.5, if the cross validatory
ANOVA p-value was ≤0.05 and if the permutation
test was passed (20 permutations, R2 > R2permutation and
Q2permutation < 0). Discriminative features were selected
based on a VIPPRED score ≥ 1.5 and absolute p (corr) ≥
0.5. The confidence interval of the selected features
was also not including 0. With this approach, only
metabolic features with strong model contribution
and high reliability were selected. Univariate statistical
analysis was performed to consistently evaluate the
filtered metabolic features and to screen for additional
metabolites. For the pilot study, univariate analysis of
variance (ANOVA) was based on arcsinh transformed
data from Progenesis QI. For the validation study,
ANOVA was performed with SIMCA and was based
on log2 transformed and Pareto scaled normalized
abundances. The false discovery rate (FDR) due to
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multiple testing was estimated according to Benjamini
Hochberg [17]. FDR corrected p-values (i.e. q-value)
threshold was set at q ≤ 0.05.
Structure and formula of the isolated discriminative
metabolic features were searched against the Human
Metabolome Database (HMDB, version 3.6) and LIPID
MAPS Structure Database (LMSD, version from Decem-
ber 6, 2016) with a mass accuracy of 8 ppm. Metabolic
features with only one adduct ion were assumed to be
[M +H]+ and [M-H]− ions in the positive and negative
ionization mode, respectively.
Results
Study cohort
In the pilot study, 10 IPF patients and 10 age- and sex-
matched healthy controls were included. The mean age
of IPF patients and of healthy controls was 67.8 respect-
ively 68.7 years. Ninety percent of all participants were
male in both groups. Lung functional measurements
showed a reduced median forced vital capacity (FVC) of
2.4 L (mean 65% predicted) in IPF patients and a median
FVC of 4.1 L (mean 115% predicted) in controls. Aver-
age 3-year mortality prediction in IPF patients was in
42.1% according to the currently used GAP staging
method (stage II) [2]. Eighty percent of IPF patients and
controls had a history of cigarette smoking.
For the validation study, blood sampling from 7 IPF
patients was performed 2 weeks after the initial pilot
study. Four recently diagnosed IPF patients and all
healthy controls were newly collected for the validation
study. One sample of the control group was excluded
due to analytical problems during sample preparation.
Eleven IPF patients and 10 healthy controls remained
for further analysis. The baseline characteristics of pa-
tients and controls of both pilot and validation study are
summarized in Table 1.
Metabolic serum profiling by UHPLC-HRMS
The differentially regulated serum metabolites in healthy
participants and IPF patients were searched for by non-
targeted metabolic profiling using UHPLC-HRMS. The
flowchart for sample preparation and analysis is illus-
trated in Fig. 1. After data processing and filtration, 2426
and 1740 metabolic features were detected in the pilot
study by UHPLC-HRMS in the positive and negative
electrospray ionization (ESI) mode, respectively. Princi-
pal component analysis (PCA) of the non-targeted meta-
bolic profiles measured by UHPLC-HRMS suggested
differences between healthy controls and IPF patients
(Fig. 2). In the negative ESI mode, one IPF sample was
defined as outlier and excluded from further statistical
analysis, otherwise multivariate and univariate statistical
analysis of the data did not isolate differentially regulated
metabolic features (data not shown). Acceptable OPLS-
DA model characteristics were obtained (Table 2) and
based on the selection criteria, 67 and 103 discriminative
Table 1 Baseline characteristics of healthy controls and IPF patients
Pilot study Validation study
Healthy IPF Healthy IPF
Subjects (male %) 10 (90) 10 (90) 10 (60) 11 (82)
Age (years) 68.7 ± 7.9 67.8 ± 8.6 32.4 ± 15.3 66.1 ± 8.6
BMI kg/m2 28.9 ± 5.1 26.9 ± 3.6 22.6 ± 2.7 26.3 ± 4.3
BMI≥ 25 kg/m2 7 5 2 6
Diabetes mellitus type 2 (n) 1 2 0 3
Hypertension 5 5 0 3
Lung function
FVC, L 4.1 ± 0.4 2.4 ± 0.5 4.5 ± 1.0 2.4 ± 0.6
FVC (% predicted) 114.6 ± 8.5 65.1 ± 11.3 94.0 ± 10.3 63.1 ± 14.3
DLCO (% predicted) 129.6 ± 31.1 43 ± 15.0 87.8 ± 11.3 44.6 ± 14.6
GAP Stage (I-III) – I - II – I- II
Smoking status
Current Smokers n (median pack years ± SD) 0 0 5 (8.2 ± 14.5) 0
Former Smokers n (median pack years ± SD) 8 (5.5 ± 5.7) 8 (25.4 ± 15.2) 0 8 (13.9 ± 13.3)
Antifibrotic therapy
Pirfenidone n (%) – 6 (60) – 6 (54.5)
Nintedanib n (%) – 3 (30) – 4 (36.4)
No antifibrotics n (%) – 1 (10) – 1 (9.1)
FVC Forced vital capacity, DLCO Diffusing capacity of the lung for carbon monoxide, BMI Body Mass Index
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features were selected by univariate and/or multivariate
analysis in the positive and negative ESI mode, respect-
ively (data not shown).
To validate our results, a new set of samples was pro-
filed by UHPLC-HRMS. After data processing and filtra-
tion, 1229 and 1059 metabolic features were detected by
UHPLC-HRMS in the positive and negative ESI mode,
respectively. Based on the PCA score plots (data not
shown), one healthy participant was considered as out-
lier and was further excluded from statistical analysis.
The PCA score plots obtained after data filtration and
exclusion of this participant are shown in Fig. 3. Similar
to the pilot study, satisfactory multivariate model param-
eters were obtained in both ionization modes (Table 2).
Based on our selection criteria, 103 and 364 discrimina-
tive features were selected by univariate and/or multi-
variate analysis in the positive and negative ESI mode,
respectively (data not shown).
To identify common metabolic features regulated be-
tween healthy participants and IPF patients in the pilot
and validation study, the retention time and m/z ratio of
the discriminative metabolic features isolated in each
study by multivariate and/or univariate analysis were com-
pared. Among them, 3 and 27 metabolic features were
commonly found in the positive and negative ionization
mode, respectively. Based on their abundance profile
(Additional file 1: Figure S1), we hypothesized that the
metabolic features mainly detected in the IPF samples
were related to drugs and/or drug metabolites. After ex-
clusion of these features, 10 metabolic features remained
differentially regulated in the pilot and were confirmed in
the validation study. Their corresponding fold changes in
abundance and potential annotations found against the
metabolite databases are summarized in Table 3.
The identity of inosine was confirmed by comparing
the retention times and fragmentation patterns obtained
Sample measurement
Data processing andfiltration
UHPLC- MS analysis  
Randomized order 
Step II : Model building with SIMCA: 
 PCA and OPLS-DA 
Positive ion mode 
Negative ion mode 
Feature selection with VIP and loading plot 
         Step III : Pairwise comparison
Data transformation 
ANOVA analysis (p  0.05) 
FDR after Benjamini and Hochberg 
(FDR adjusted p  0.05) 
Multivariate statistical analysis
Step I: Processing with Progenesis QI 
lock-mass correction
chromatographic alignment
ion pattern deconvolution
Extraction of features 
Exclusion of ion patterns with: 
Fold change >2 in blanks vs. QC 
QC CV > 30% 
Peak width < 0.05 min 
z > 1 
Normalized abundance < 200 
(ESI+)/150 (ESI-) 
Retention time <0.5, >10.5 min 
Pilot study Validation study
20 samples
10 IPF patients  
10 healthy controls 
1 injection replicate 
22 samples
11 IPF patients  
11 healthy controls 
2 injection replicates 
Univariate statistical analysis
Remaining 
samples: 
11 IPF patients  
10 healthy controls 
2 injection replicates 
Positive ion mode 
 features included 
38 features selected 
Negative ion mode 
 features included 
35 features selected
Positive ion mode 
 features included 
34 features selected
Negative ion mode 
 features included 
38 feature selected
Positive ion mode 
-arc sinh transformed 
-44 features selected 
(FDR p < 0.05) 
Positive ion mode 
-Abundances avaraged  
-Log10 transformed 
108 features selected 
(FDR p < 0.05)
Identification
Step IV: Metabolite identification search 
HMDB database search 
LipidMaps 
Negative ion mode 
-arc sinh transformed 
-0 feature selected 
(FDR p < 0.05) 
Negative ion mode 
-Abundances avaraged  
-Log10 transformed 
364 features selected 
(FDR p < 0.05)
Fig. 1 Flowchart for sample measurement, data processing and statistical analysis. [60]
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in serum to an authentic inosine standard. This purine
metabolite was upregulated in the pilot study and down-
regulated in the validation study. Only three metabolic
features eluting at 5.94 min (m/z = 332.242) and
9.59 min (m/z = 512.334 in the positive ESI mode and
m/z = 556.325 in the negative ESI mode) were signifi-
cantly upregulated in IPF patients in both studies.
The metabolic features eluting at 5.94 min was poten-
tially assigned against the HMDB database to 3-
hydroxydecanoyl carnitine (chemical formula C17H33NO5,
mass error − 2.7 ppm, isotope similarity 96%). The detec-
tion of the characteristic acylcarnitine fragment
[C4H5O2]
+ at m/z 85.0284 was confirmed by UHPLC-
TWIM-MS measurement (mass error − 4.8 ppm,
Additional file 2: Figure S2). No significant differences
were found in the global acylcarnitine profile (data not
shown, profile extracted as in Bally et al. [18]).
At 9.59 min, three discriminative metabolic features
were two times more abundant in the serum of IPF
patients compared to healthy participants (Table 3,
m/z = 512.334 in the positive ESI mode, m/z = 556.325
and 496.303 in the negative ESI mode, with the latter
being significant only in one study). Presumably, these
co-eluting ions belonged to the same metabolic fea-
tures. In the negative ESI mode, the detected ion pat-
tern agreed with a phosphatidylcholine (PC) or
sphingomyelin [M-CH3]
− and [M + CHOO]− ions.
These ion patterns were confirmed by the analysis of
PC lipid standards (data not shown) and agreed with
the literature [19, 20]. The MS/MS spectra acquired
in the positive and negative ESI mode (DDA experi-
ments, Additional file 3: Figure S3) further suggested
the detection of a LysoPC with the chemical formula
C24H50NO8P (mass error − 1.0 ppm, isotope similarity
98%). No LysoPC structure matching the MS data
was found against the LIPID MAPS database and the
literature. Therefore, we assumed a LysoPC structure
with an ether or hydroxylated acyl chain in the sn-1
or sn-2 position (Scheme 1). We further characterized
this unknown LysoPC with TWIM-MS and measured
a CCS of 227.5 Å2 for the protonated ion (Table 4).
Excellent CCS agreements with the literature (Table 4,
CCS error < 1.1%) were obtained for the PC standard
mixture confirming the excellent inter-laboratory re-
producibility of CCS values [16]. A single TWIM peak
was detected for the unknown LysoPC, which sug-
gested the detection of a single LysoPC having a
compacter conformation than PC(16:0/0:0). To our
knowledge, the influence of ether or hydroxylated acyl
chain on the LysoPC CCS has not been reported. It
is therefore difficult to hypothesize the most probable
structure for this unknown LysoPC based on the
TWIM-MS measurement. The abundance profiles of
all significantly upregulated metabolic features de-
tected in the pilot and validation study (3-
Fig. 2 PCA score plots of the healthy participants and IPF patients of
the pilot study measured in the (a) positive and (b) negative ESI mode
Table 2 Characteristics of the OPLS-DA models for the pilot and validation study sets analyzed in positive (ESI+) and negative (ESI-)
ESI mode
Study Ionisation Number of samples R2(cum) Q2(cum) CV ANOVA p-value Permutation test
Pilot ESI+ 20 0.894 0.599 0.0058 R2 = 0.734
Q2 = −0.209
Validation ESI+ 21 0.903 0.742 0.00014 R2 = 0.694
Q2 = −0.318
Pilot ESI- 19 0.872 0.503 0.0339 R2 = 0.767
Q2 = −0.299
Validation ESI- 21 0.878 0.721 0.0003 R2 = 0.66
Q2 = −0.447
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hydroxydecanoyl carnitine, and 2 metabolic features
of LysoPC) are shown in Fig. 4.
Discussion
After excluding potential drugs and drug metabolites, ten
metabolic features were isolated in serum from IPF
patients by non-targeted UHPLC-HRMS based metabolo-
mics. Among them, 3 metabolic features were significantly
upregulated in IPF patients in both, pilot and validation
study. Based on the MS data and the databases, we hy-
pothesized the detection of 3-hydroxydecanoyl carnitine
and a LysoPC, the second as a potential precursor for
lysophosphatidic acid (LPA) [21].
Identification of differences between IPF and healthy
individuals by biomarker is important for diagnosis and
prognosis and supports the clinician for evaluation of in-
dividual treatment responses. In addition, heterogeneity
of disease course suggests different pathophysiological
phenotypes in IPF. A recent study identified molecules
of the autotaxin-lysoPA pathway by metabolomics ana-
lysis equally for patients with COPD [22]. In this study,
lung functional parameters in males were associated
with LPA subspecies levels in COPD [22]. Due to the
predominant male patients and small number of partici-
pants we are unable to further investigate a gender asso-
ciation in our study.
In the positive ESI mode, we detected a metabolic fea-
ture (m/z 332.242 at a retention time of 5.94 min) with
possible identification of 3-hydroxydecanoyl carnitine, a
Fig. 3 PCA score plots of the healthy participants and IPF patients of
the validation study measured in the (a) positive and (b) negative
ESI mode
Table 3 LC-MS characteristics (retention time, m/z ratio) and fold changes of the metabolic features isolated by multivariate and/or
univariate analysis (FDR ≤ 0.05) in the pilot and validation study
Study Compound ID Potential ID [adduct] Ionisation m/z RT
(min)
Fold change IPF/
Healthy
FDR
(Univariate)
Multivariate
Pilot
Validation
5.94_332.2423m/z
5.94_332.2419m/z
3-hydroxydecanoyl
carnitine [M+H]+
ESI+ 332.2423
332.2419
5.94
5.94
4.0
25.9
0.047
0.003
no
no
Pilot
Validation
9.59_511.3269n
9.59_511.3259n
LysoPC
[M+H]+, [M+Na]+,
[M+K]+
ESI+ 512.3342
512.3332
9.59
9.59
1.9
1.9
0.037
0.008
yes
yes
Pilot
Validation
9.59_496.3026m/z
9.58_496.3029m/z
LysoPC
[M-CH3]
-
ESI- 496.3026
496.3029
9.59
9.59
1.6
2.0
0.11
4.87 10−4
yes
yes
Pilot
Validation
9.59_556.3248m/z
9.59_556.3245m/z
LysoPC
[M+CHOO]-
ESI- 556.3248
556.3245
9.59
9.59
1.9
2.1
0.048
5.19 10−4
yes
yes
Pilot
Validation
2.43_267.0728m/z
2.38_267.0737m/z
Inosine
[M-H]-
ESI- 267.0728
267.0737
2.43
2.38
1.8
0.7
0.22
0.044
yes
yes
Pilot
Validation
8.77_370.1807n
8.38_369.1738m/z
Androsterone
sulfate [M-H]−
ESI- 369.1734
369.1738
8.77
8.38
0.4
0.3
0.22
0.03
yes
yes
Pilot
Validation
0.88_195.8107m/z
0.65_195.8115m/z
ESI- 195.8107
195.8115
0.88
0.65
0.8
0.9
0.25
0.02
yes
yes
Pilot
Validation
0.88_197.8076m/z
0.65_197.8090m/z
ESI- 197.8076
197.8090
0.88
0.65
0.8
0.9
0.23
0.02
yes
yes
Pilot
Validation
0.88_199.8045m/z
0.65_199.8057m/z
ESI- 199.8045
199.8057
0.88
0.65
0.8
0.9
0.24
0.03
yes
yes
Pilot
Validation
8.57_371.1879m/z
8.57_371.1879m/z
ESI- 371.1879
371.1889
8.57
8.60
0.3
0.2
0.24
0.04
yes
no
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medium-chain acylcarnitine, which was upregulated in
serum of IPF patients (pilot FC 4.0, validation FC 25.9).
We did not detect sufficient hydroxycarnitines species to
further evaluate their profile because of the insufficient
sensitivity of our method. In addition, no significant dif-
ferences were found in the global acylcarnitine profile.
In contrast, medium-chain acylcarnitines were decreased
in lung tissue from IPF patients in a recent metabolo-
mics study [23]. According to the authors this may be
due to an impaired transport of fatty acids into the mito-
chondria [23].
A metabolic profiling study using gas-chromatography
coupled to mass spectrometry of IPF lung tissue showed
that the purine metabolites inosine and hypoxanthine
were increased compared to normal lung tissue [24].
Inosine is the precursor for adenosine. In experimental
models, adenosine levels have been associated with dis-
ease progression for lung fibrosis and could be abrogated
by adenosine inhibitor dipyridamole [25]. Extracellular
adenosine levels are associated with the progression and
exacerbation of pulmonary fibrosis [25]. In addition,
adenosine receptors were increased in lungs form IPF
patients [26]. Purinergic signaling and scarring of fibrotic
tissue have been largely associated [27]. Interestingly, in
our study, we found a discordant regulation of inosine
between the pilot and the validation set. While in the
age-matched pilot study serum levels of inosine were
increased in IPF patients, the validation study showed an
opposing result. A possible explanation is the lack of
age-matched validation cohort. Age-dependent serum
adenosine deaminase activity may have had an impact
on this result [28].
In our study, we consistently identified a LysoPC in
serum from IPF patients. LysoPC is a precursor of LPA,
which is a bioactive glycerophospholipid. There are mul-
tiple LPA types differing in length and degree of satur-
ation of the fatty acid [29]. LPA is involved in various
processes as fibrosis, systemic sclerosis, cancer, inflam-
mation, atherosclerosis, obesity, asthma, multiple scler-
osis, neuropathic pain or embryonal implantation [30–
39]. LPA induces fibrosis in the lung, kidney and liver by
epithelial cell death, vascular leakage and fibroblast mi-
gration and proliferation [30, 40–42].
The wide range of biological effects can be explained
by multiple LPA receptors. LPA mediates its responses
via at least six LPA receptors [21]. Pro-fibrotic effects
are induced by activation of the specific LPA receptor
LPA1 [21]. Both genetic suppression of LPA-receptor 1
and antagonism of the enzyme autotaxin prevent pul-
monary fibrosis [42–44]. LPA1-deficient mice did not de-
velop pulmonary fibrosis after bleomycin injury [42].
Additionally, LPA via LPA2 induces αvβ6 integrin-
mediated transforming growth factor-β (TGF-β) activa-
tion in bronchial epithelial cells [45]. It was shown in
O
O
HOH
O O
N
+ CH3
CH3
CH3
P
O
-
O
O
CH3
O
O
HOH
O O
N
+ CH3
CH3
CH3
P
O
-
OOH
CH3
Scheme 1 Potential structures of the LysoPC which was elevated in serum of IPF patients compared to controls. For simplification, only the sn-1
isomers are represented
Table 4 CCS values obtained from the ion mobility measurements of the lipid standards and the unknown LysoPC. Results shown
are averages from three sample analysis
Component [M + H]+ Formula Average RT (min) Average CCS (Å2) RSD CCS (%) Literature CCS (Å2) CCS error (%)
Unknown LysoPC C24H50NO8P 9.55 227.5 0.0
PC(16:0/0:0) C24H50NO7P 11.01 237.9 0.2 236 [16] 0.8
PC(18:2/0:0) C26H50NO7P 10.83 234.7 0.1
PC(18:0/0:0) C26H54NO7P 11.46 245.2 0.1 246 [16] 1.1
PC(12:0/12:0) C32H64NO8P 11.96 269.4 0.1 272.4 [19] −1.1
PC(14:0/14:0) C36H72NO8P 12.52 281.9 0.2 282.9 [19] −0.4
PC(18:1/18:1) C44H84NO8P 13.38 300.6 0.2
CCS Collision cross section
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another study, that LPA2 knockout mice did not develop
pulmonary fibrosis after bleomycin application. More-
over, the expression of TGF-β in human lung fibroblasts
was inhibited [46].
The source of LPA is unclear. There are at least two dif-
ferent sources of LPA production. One is the hydrolysis of
phosphatidic acids, which are located in cell membranes,
by phospholipase A1 and A2. But the majority of LPA is
produced by the enzymatic cleavage of LysoPC and lyso-
phosphatidylserine by lysophospholipase D activity of the
enzyme autotaxin (ATX) [47–49]. In IPF, epithelial cell in-
jury, specifically of type 2 alveolar epithelial cells, is
thought to initiate the fibrotic process [9]. After lung
injury, dipalmitoylphosphatidylcholine (DPPC), as major
surfactant lipid component, is degraded to LysoPC by
phospholipase A2 activity by type 2 alveolar epithelial cells
[50]. As explained above, LysoPC is a precursor of LPA
and converted by the enzyme autotaxin (ATX) [21]. LPA
via LPA1 promotes epithelial cell apoptosis after lung in-
jury [51]. But also platelet activation can lead to LPA via
autotaxin [52]. In IPF a prothrombotic state is recognized
and platelet activation is increased compared to controls
[53]. Increased platelet activation might contribute to ele-
vated LPA levels in IPF. Previous studies showed increased
level of LPA in the bronchoalveolar lavage fluid and ex-
haled breath condensate of IPF patients [42, 54].
In addition, COPD metabolomics studies also revealed al-
teration of LPA pathway [22]. LPA pathway has been associ-
ated with several different lung disease including hyperoxic
lung injury and asthma [36, 55, 56]. As therapeutic approach
to interrupt the LysoPC - LPA axis, an oral inhibitor of auto-
taxin (GLPG1690) is currently evaluated in a Phase 2 study
for IPF patients [57, 58]. If the production of LPA is reduced
by inhibition of autotaxin, both LPA1 and LPA2 pathways
would be targeted [58]. In our study, LPA was not detectable
in our samples due to the analytical method. However, we
Fig. 4 Normalized abundances of the common significantly regulated metabolic features detected in the (a) pilot study and (b) validation study.
The metabolic feature eluting at 5.94 min was assigned to 3-hydroxydecanoyl carnitine ([M + H]+, m/z = 332.242), the ones eluting at 9.59 min to
the LysoPC (neutral mass 511.327 amu, and [M + CHOO]− at m/z = 556.325)
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were able to show upregulated LysoPC in serum of IPF
patients, indicating the crucial role of LysoPC-LPA pathway
in IPF. Now, our findings need to be confirmed by different
methods in a larger cohort of IPF patients including correl-
ation to clinical parameters and disease severity.
Conclusions
In our study, we detected by global UHPLC-HRMS based
metabolic profiling an increased serum level of a potential
LysoPC and 3-hydroxydecanoyl carnitine in IPF patients
compared to healthy controls. If confirmed in a larger co-
hort, the LysoPC might represent a potential marker for
diagnostic and monitoring of IPF. The clinical meaning of
this potential metabolite and its significance need to be
evaluated in future studies. Global metabolic profiling by
UHPLC-HRMS is a promising approach to detect possibly
relevant pathophysiological pathways and potential serum
biomarkers in IPF.
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Additional file 1: Figure S1. Heat maps representing the log10-
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